Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

August 19, 2024

Epidemiology of metabolic dysfunction-associated steatotic liver disease

Zobair M. Younossi, Markos Kalligeros, Linda Henry

Clin Mol Hepatol. 2025;31(Suppl):S32-S50.

As the rates of obesity and type 2 diabetes (T2D) continue to increase globally, so does the prevalence of metabolic dysfunction–associated steatotic liver disease (MASLD). Currently, 38% of all adults...

Review

June 27, 2024

Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Yue Wang, Sherlot Juan Song, Yichong Jiang, et al.

Clin Mol Hepatol. 2025;31(Suppl):S51-S75.

In managing metabolic dysfunction-associated steatotic liver disease, which affects over 30% of the general population, effective noninvasive biomarkers for assessing disease severity, monitoring disease progression, predicting the development of liver-related...

Review

August 5, 2024

Precision medicine and nucleotide-based therapeutics to treat steatotic liver disease

Andrea Caddeo, Stefano Romeo

Clin Mol Hepatol. 2025;31(Suppl):S76-S93.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a complex multifactorial disease and becoming the leading cause of liver-related morbidity and mortality. MASLD spans from isolated steatosis to metabolic dysfunction-associated steatohepatitis...

Review

November 28, 2024

Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease

Huma Saeed, Luis Antonio Díaz, Antonio Gil-Gómez, et al.

Clin Mol Hepatol. 2025;31(Suppl):S94-S111.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a significant global health issue, affecting over 30% of the population worldwide due to the rising prevalence of metabolic risk factors such as...

Review

October 31, 2024

Alcohol-associated liver disease: Natural history, management and novel targeted therapies

Edilmar Alvarado-Tapias, Elisa Pose, Jordi Gratacós-Ginès, et al.

Clin Mol Hepatol. 2025;31(Suppl):S112-S133.

Alcohol consumption is a leading cause of preventable morbidity and mortality worldwide and the primary cause of advanced liver disease. Alcohol use disorder is a chronic, frequently relapsing condition characterized...

Review

January 22, 2025

Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0

Di Wu, Jia-Horng Kao, Teerha Piratvisuth, et al.

Clin Mol Hepatol. 2025;31(Suppl):S134-S164.

As new evidence emerges, treatment strategies toward the functional cure of chronic hepatitis B are evolving. In 2019, a panel of national hepatologists published a Consensus Statement on the functional...

Review

November 14, 2024

Prospect of emerging treatments for hepatitis B virus functional cure

Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, et al.

Clin Mol Hepatol. 2025;31(Suppl):S165-181.

Functional cure, defined as sustained hepatitis B surface antigen (HBsAg) seroclearance with unquantifiable hepatitis B virus (HBV) DNA at 24 weeks off treatment, is a favorable treatment endpoint in chronic...

Review

November 21, 2024

Mechanisms of hepatocellular carcinoma and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis B

Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, et al.

Clin Mol Hepatol. 2025;31(Suppl):S182-S195.

Chronic hepatitis B (CHB) poses a major global public health challenge and is a leading cause of cirrhosis and liver cancer. Hepatic steatosis is common in individuals with CHB compared...

Review

November 11, 2024

Hepatitis E as a trigger for acute-on-chronic liver failure

Maria Buti, Juan Carlos Ruiz-Cobo, Rafael Esteban, et al.

Clin Mol Hepatol. 2025;31(Suppl):S196-S204.

Acute hepatitis E virus (HEV) infection is typically self-limiting and has a favourable prognosis. However, certain populations such as patients with pre-existing chronic liver disease may experience severe manifestations, including...

Review

February 18, 2025

Prediction and prevention of post-procedural bleedings in patients with cirrhosis

Alix Riescher-Tuczkiewicz, Pierre-Emmanuel Rautou

Clin Mol Hepatol. 2025;31(Suppl):S205-S227.

Although post-procedural bleedings are infrequent in patients with cirrhosis, they are associated with significant morbidity and mortality. Therefore, predicting and preventing such bleedings is important. Established predictors of post-procedural bleeding...

Review

December 26, 2024

Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment

Soo Young Hwang, Pojsakorn Danpanichkul, Vatche Agopian, et al.

Clin Mol Hepatol. 2025;31(Suppl):S228-S254.

Hepatocellular carcinoma (HCC) is a major global burden, ranking as the third leading cause of cancer-related mortality. HCC due to chronic hepatitis B virus (HBV) or C virus (HCV) infection...

Review

November 28, 2024

Liquid biopsy in hepatocellular carcinoma: Challenges, advances, and clinical implications

Jaeho Park, Yi-Te Lee, Vatche G. Agopian, et al.

Clin Mol Hepatol. 2025;31(Suppl):S255-S284.

Hepatocellular carcinoma (HCC) is an aggressive primary liver malignancy often diagnosed at an advanced stage, resulting in a poor prognosis. Accurate risk stratification and early detection of HCC are critical...

Review

August 19, 2024

Criteria and prognostic models for patients with hepatocellular carcinoma undergoing liver transplantation

Meng Sha, Jun Wang, Jie Cao, et al.

Clin Mol Hepatol. 2025;31(Suppl):S285-S300.

Hepatocellular carcinoma (HCC) is a leading cause of cancer-associated death globally. Liver transplantation (LT) has emerged as a key treatment for patients with HCC, and the Milan criteria have been...

Review

December 10, 2024

Prediction and management of small-for-size syndrome in living donor liver transplantation

Jia-hao Law, Alfred Wei-Chieh Kow

Clin Mol Hepatol. 2025;31(Suppl):S301-S326.

Small-for-size syndrome (SFSS) remains a critical challenge in living donor liver transplantation (LDLT), characterized by graft insufficiency due to inadequate liver volume, leading to significant postoperative morbidity and mortality. As...

Review

December 26, 2024

Liver organoids: Current advances and future applications for hepatology

Yohan Kim, Minseok Kang, Michael Girma Mamo, et al.

Clin Mol Hepatol. 2025;31(Suppl):S327-S348.

The creation of self-organizing liver organoids represents a significant, although modest, step toward addressing the ongoing organ shortage crisis in allogeneic liver transplantation. However, researchers have recognized that achieving a...

Viewed By 7419	MAFLD: How is it different from NAFLD?
Viewed By 7021	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 5609	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 5362	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4791	Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Cited By 298	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 270	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 186	MAFLD: How is it different from NAFLD?
Cited By 93	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 92	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis